Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. Here she highlights the
Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. With the rise of
Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. Here, she discusses how
With a 20-year experience in cancer immunotherapies, Neil Sheppard, comes back on the early days of CAR-T cell therapies, talking about Novartis, U. Penn, Juno, Kite, …
Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains how the 3D organization of cells positively impacts cell division, reducing mitotic errors
Working with biomimetic 3D cultures of pluripotent stem cells, Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, discusses how mimicking the 3D
Working with biomimetic 3D cultures of pluripotent stem cells, Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, discusses how mimicking the 3D
Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem
Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem
Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem
Shin Kawamata, MD, PhD, Director of the R&D Center for Cell Therapy at the FBRI (Kobe, Japan) stresses the importance of controlling the quality of iPSC banks at a very
Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies.
The webcast In the Stem Cell Jungle becomes a blog about pluripotent stem cells and their applications in cell therapy. Maxime Feyeux, CSO of TreeFrog, who was hosting the webcast on youtube, is now editor of the blog, which brings together developmental biology insights about pluripotent stem cells (both iPS & ES cells) and views from the industry about iPS-derived cell therapies for regenerative medicine and immune-oncology. The blog is also featuring free access resources, such as a whitebook about the epiblast rosette and how to leverage this in vivo structure to manufacture iPSCs at scale using biomimetic technologies such as C-Stem, as well as a list of cell therapy programs based on pluripotent stem cells in clinical trial.